Results 51 to 60 of about 3,389 (131)
Actividad de una nueva combinación de β-lactámico e inhibidor de β-lactamasas (imipenem/relebactam)
[spa] Pseudomonas aeruginosa es uno de los patógenos oportunistas con mayor capacidad de desarrollar resistencia a antibióticos, ya sea por mutaciones cromosómicas o por la adquisición de genes de resistencia; lo que conlleva a la necesidad de ...
Orellana Ponce, Rocío Antonela
core
Imipenem/cilastatin/relebactam is a β-lactam/β-lactamase inhibitor that has been recently FDA approved for complicated intra-abdominal and urinary tract infections under the brand name Recarbrio®.
Paul Fimognari +8 more
core +1 more source
International audienceAbstract Objectives : Mycobacterium abscessus is the most frequent of the rapidly growing mycobacteria responsible for lung infections in patients suffering from cystic fibrosis and COPD.
Bitar, Maria +4 more
core +1 more source
Relebactam, a potent β-lactamase inhibitor, in combination with Primaxin is an FDA-approved (Recarbrio) treatment for serious and antibiotic-resistant bacterial infections. An efficient synthesis of key chiral piperidine intermediate 1 suitable for large-
Aaron Dumas +21 more
core +1 more source
Background and Objectives: Infections caused by non-tuberculous mycobacteria (NTM), including Mycobacterium abscessus complex (MABc), are increasing globally and are notoriously difficult to treat due to the intrinsic resistance of these bacteria to many
Verónica Gonzalez-Galán +12 more
core +1 more source
Figure S1. Minimum inhibitory concentrations (MIC50/90, expressed in Îźg/mL) for imipenem (A) and imipenem with 4âÎźg/mL relebactam (B), mapped onto a dendrogram of P. aeruginosa PDC alleles.
Douglas Wisniewski (2404219) +13 more
core +1 more source
Table S1. P aeruginosa isolate sources. Table S2. Primers used in the construction of P. aeruginosa RND-overexpressing strains. Table S3. Inoculum effect control data. Table S4.
Douglas Wisniewski (2404219) +13 more
core +1 more source
In the United States, carbapenem resistance in Pseudomonas aeruginosa is linked to the regulation of chromosomal resistance determinants, AmpC and OprD.
Nancy D. Hanson, Shawn Freed, Jr
core +1 more source
[eng] Objectives: To analyse the dynamics and mechanisms of stepwise resistance development to ceftolozane/tazobactam and imipenem/relebactam in XDR Pseudomonas aeruginosa clinical strains.
Gomis-Font, María A. +6 more
core +1 more source
In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in Pseudomonas aeruginosa [PDF]
[eng] Pseudomonas aeruginosa, is a major cause of nosocomial and chronic infections, being considered a paradigm of antimicrobial resistance development.
Gomis Font, Maria Antonia
core

